NAT CANCER 润色咨询

Nature Cancer

出版年份:暂无数据 年文章数:187 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:暂无数据 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2023-11-09 ms4000000924673027 来自广东省

    请问under consideration21天了,是什么情况,需要催一下吗

    18

    展开18条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-11-11 ms3000000081429133

    偏重的研究方向:肿瘤
    经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗

    12

    展开12条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-09-09 许腾

    10天了,一直是manstription under consideration,无奈

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2023-09-10 shyhihihi 来自佛罗里达

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究
    经验分享:直接投稿(没有pre-submission inquiry)
    manuscript under consideration (2周左右)
    Editor Decision Started
    邮件通知送外审
    经验1 (中稿):
    然后Manuscript under consideration(一个月左右)
    通知改稿
    重投Manuscript submitted
    Manuscript under consideration(2周左右)
    原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)
    一共历时3个多月,算是非常顺利的一次。
    ————————————
    经验二(拒稿):
    Manuscript under consideration (13 days)
    Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~)

    4

    展开4条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2023-04-21 ms1000000589600011 来自瑞典

    他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2023-12-02 Tou gao小菜鸡 来自广东省

    偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究
    经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2023-09-25 ms8000001567143208 来自北京

    请问各位大佬,这本杂志含金量怎么样,好投么

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2023-08-08 1881f7238cm 来自广东省

    投过去第13天,依然是Manuscript under consideration

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-05-03 docL

    有没有人分享下投稿经验和时间节点呢,万分感谢

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了,是什么情况,需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向:肿瘤<br>经验分享:投稿后Manuscript under consideration这个状态已经持续了10天了,有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248231, encodeId=adf412482319d, content=10天了,一直是manstription under consideration,无奈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ1j9Jxo3CX7NW9QWF4ov1c76uJHMv5Tje8Fh2y4D91UDwGxHMqqKu579eGE3vWuFewziacOR0uicLQ/132, createdBy=244a5261403, createdName=许腾, createdTime=Fri Sep 09 23:07:04 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:临床试验;癌症免疫治疗;癌症基础研究<br>经验分享:直接投稿(没有pre-submission inquiry)<br>manuscript under consideration (2周左右)<br>Editor Decision Started <br>邮件通知送外审<br>经验1 (中稿):<br>然后Manuscript under consideration(一个月左右)<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration(2周左右)<br>原则上接收 (原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收)<br>一共历时3个多月,算是非常顺利的一次。<br>————————————<br>经验二(拒稿):<br>Manuscript under consideration (13 days)<br>Editor Decision Started(邮件通知不感兴趣,编辑部直接拒掉,哭~~~), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次我们发了后邀请投稿不过被拒,转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿,看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向:癌症;癌症免疫治疗;癌症基础研究<br>经验分享:请问presubmission inquiry编辑回复邀请投稿送审机会大吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2159586, encodeId=9ee421595866d, content=请问各位大佬,这本杂志含金量怎么样,好投么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ba8492816, createdName=ms8000001567143208, createdTime=Mon Sep 25 13:20:20 CST 2023, time=2023-09-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2151775, encodeId=763c2151e7585, content=投过去第13天,依然是Manuscript under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa052104051, createdName=1881f7238cm, createdTime=Tue Aug 08 15:33:47 CST 2023, time=2023-08-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1216585, encodeId=7b751216585fe, content=有没有人分享下投稿经验和时间节点呢,万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Tue May 03 17:15:54 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185744, encodeId=549b1185e449e, content=IF 20以上了,已经很难盘了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=178, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220506/390e3db992e54051876ea8f2b93fdfc3/8b383d5bed0342e7908a61cdfe500fcb.jpg, createdBy=64682431106, createdName=123b79d2m38(暂无昵称), createdTime=Tue Jan 18 20:28:49 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 123b79d2m38(暂无昵称)

    IF 20以上了,已经很难盘了

    1

    展开1条回复
共76条页码: 1/8页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分